# Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.

> **NCT03208790** · PHASE2 · COMPLETED · sponsor: **Cairo University** · enrollment: 48 (actual)

## Conditions studied

- Premalignant Lesion

## Interventions

- **DRUG:** Nigella sativa buccal tablets 10mg
- **DRUG:** Nigella sativa buccal tablets 5mg
- **DRUG:** Placebo buccal tablets

## Key facts

- **NCT ID:** NCT03208790
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-30
- **Primary completion:** 2020-03-12
- **Final completion:** 2020-03-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03208790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03208790, "Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03208790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*